Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
5.49
-0.14 (-2.49%)
At close: Oct 1, 2026, 4:00 PM EDT
5.50
+0.01 (0.18%)
After-hours: Oct 1, 2026, 7:30 PM EDT
Aligos Therapeutics Employees
Aligos Therapeutics had 82 employees as of December 31, 2025. The number of employees increased by 12 or 17.14% compared to the previous year.
Employees
82
Change (1Y)
12
Growth (1Y)
17.14%
Revenue / Employee
$384,366
Profits / Employee
-$926,366
Market Cap
34.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 82 | 12 | 17.14% |
| Dec 31, 2024 | 70 | 4 | 6.06% |
| Sep 30, 2024 | 68 | 0 | - |
| Jun 30, 2024 | 68 | 0 | - |
| Mar 31, 2024 | 67 | -2 | -2.90% |
| Dec 31, 2023 | 66 | -17 | -20.48% |
| Sep 30, 2023 | 68 | -21 | -23.60% |
| Jun 30, 2023 | 68 | -21 | -23.60% |
| Mar 31, 2023 | 69 | -26 | -27.37% |
| Dec 31, 2022 | 83 | -10 | -10.75% |
| Sep 30, 2022 | 89 | 3 | 3.49% |
| Jun 30, 2022 | 89 | 3 | 3.49% |
| Mar 31, 2022 | 95 | 26 | 37.68% |
| Dec 31, 2021 | 93 | 19 | 25.68% |
| Sep 30, 2021 | 86 | 13 | 17.81% |
| Jun 30, 2021 | 86 | 19 | 28.36% |
| Mar 31, 2021 | 69 | 8 | 13.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Seres Therapeutics | 66 |
| BeyondSpring | 44 |
| Quince Therapeutics | 38 |
| Actinium Pharmaceuticals | 27 |
| PDS Biotechnology | 21 |
| LeonaBio | 19 |
| Quantum BioPharma | 17 |
ALGS News
- 22 days ago - Aligos Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Aligos Therapeutics to Present at the Cantor Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Aligos Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - GlobeNewsWire
- 1 month ago - Aligos Therapeutics Earnings release: Q2 2026 - Filings
- 1 month ago - Aligos Therapeutics Quarterly report: Q2 2026 - Filings
- 1 month ago - Aligos Therapeutics reports Q2 EPS (14c), consensus ($1.38) - TheFly
- 2 months ago - Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 - GlobeNewsWire